cvot tirzepatide Key milestones of tirzepatide in the treatment of diabetes, obesity and...

SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I

22.54

★★★★☆4.8 (126)

Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function

24.37

★★★★★4.9 (98)

Effects of tirzepatide on adjudicated cardiovascular events in

29.89

★★★★★5.0 (157)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

20.23

★★★★★4.7 (84)

Manjaro* controversial amp Cardiovascular outcomes: In SURPASS-CVOT (a large CVOT in patientswith type 2 diabetes and established atherosclerotic cardiovascular disease) tirzepatide demonstrated non nferiority to dulaglutide for the 3-point major

20.95

★★★★★4.9 (203)

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism

22.32

★★★★★5.0 (176)

TIRZEPATIDE (COAGONISTA GIP/GP1): DESARROLLO CLINICO SURPASS

29.02

★★★★★4.8 (132)